Cita APA

Bellone, S., Black, J., English, D. P., Schwab, C. L., Lopez, S., Cocco, E., . . . Santin, A. D. (2015). Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine serous papillary carcinoma cell lines in vitro. Am J Obstet Gynecol.

Chicago Style Citation

Bellone, Stefania, et al. "Solitomab, an EpCAM/CD3 Bispecific Antibody Construct (BiTE®), Is Highly Active against Primary Uterine Serous Papillary Carcinoma Cell Lines in Vitro." Am J Obstet Gynecol 2015.

Cita MLA

Bellone, Stefania, et al. "Solitomab, an EpCAM/CD3 Bispecific Antibody Construct (BiTE®), Is Highly Active against Primary Uterine Serous Papillary Carcinoma Cell Lines in Vitro." Am J Obstet Gynecol 2015.